secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001157523-24-000027
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock provides 2024 pipeline update; Phase 3 SMA trial topline data expected Q4 2024
--------------------------------------------------------------------------------

- Cash and equivalents of ~$280M as of Dec 31, 2023; projected to fund operations into H2 2025.
- Enrollment completed for apitegromab pivotal Phase 3 SAPPHIRE in SMA; topline data expected Q4 2024.
- Phase 2 proof-of-concept trial of apitegromab with GLP-1 RA in obesity to start mid-2024.
- SRK-439 IND for obesity planned in 2025; preclinical data at Keystone Symposia in Feb 2024.
- Presenting at J.P. Morgan Healthcare Conference on Jan 9, 2024 at 1:30 p.m. PT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752324000027/0001157523-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752324000027/a53878319.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer